Supernus Pharmaceuticals (NASDAQ: SUPN) and Assembly Biosciences (NASDAQ:ASMB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Profitability

This table compares Supernus Pharmaceuticals and Assembly Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals 41.10% 30.73% 19.48%
Assembly Biosciences N/A -68.83% -43.63%

Risk & Volatility

Supernus Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Supernus Pharmaceuticals and Assembly Biosciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals 0 2 4 0 2.67
Assembly Biosciences 0 0 2 0 3.00

Supernus Pharmaceuticals currently has a consensus target price of $48.33, indicating a potential upside of 11.88%. Assembly Biosciences has a consensus target price of $35.00, indicating a potential upside of 40.73%. Given Assembly Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Supernus Pharmaceuticals.

Earnings and Valuation

This table compares Supernus Pharmaceuticals and Assembly Biosciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Supernus Pharmaceuticals $252.59 million 8.67 $82.36 million $1.95 22.15
Assembly Biosciences $3.04 million 142.05 -$50.92 million ($2.74) -9.08

Supernus Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

92.8% of Supernus Pharmaceuticals shares are held by institutional investors. Comparatively, 68.9% of Assembly Biosciences shares are held by institutional investors. 6.7% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 19.6% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Supernus Pharmaceuticals beats Assembly Biosciences on 9 of the 13 factors compared between the two stocks.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company’s neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

About Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.